The Team

Dr. Marco Bortolato

Dr. Marco Bortolato is a distinguished physician-scientist whose translational research bridges molecular neuroscience and behavioral pharmacology. With a deep commitment to understanding and treating complex neuropsychiatric conditions, he designs and tests innovative models and therapies—especially those exploiting neurosteroids and cannabinoid signaling pathways.

Bortolato is a member of several professional organizations, including the International Society for Psychoneuroendocrinology, the International Behavioral and Neural Genetics Society, and the International Society for Behavioral Neuroscience.

Daniel Michalow

Daniel Michalow is an investor and former hedge fund executive who graduated from Harvard University. He built a reputation for leadership in global macro strategies and for shaping investment approaches at one of the world’s most influential hedge funds. Today, he remains active as an investor and serves as a trustee of the Homo reciprocans Foundation, continuing his work in finance and philanthropy.

Liz Schwarzbach

Elizabeth has over 25 years of experience in biopharma and academia drug discovery and development. She found her passion for pharmacology as a biologist in Merck Research Labs, later completing her doctorate in neuropharmacology at the University of Pennsylvania School of Medicine. After gaining growth, portfolio, and investment strategy experience at L.E.K. Consulting’s Life Sciences practice, she transitioned to GlaxoSmithKline R&D Strategy team. Elizabeth served as the Chief Business Officer (CBO) at the New York Stem Cell Foundation (NYSCF) Research Institute and is currently the CBO of BigHat Biosciences.